VCANBIO CELL & GENE ENGINEERING CORP., LTD Vcanbio Cell & Gene Engineering Corp., Ltd Stock
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.33 CNY | +1.24% |
|
+4.95% | -19.44% |
| Sales 2021 | 1.54B 212M | Sales 2022 | 1.55B 215M | Capitalization | 7.96B 1.1B |
|---|---|---|---|---|---|
| Net income 2021 | 155M 21.41M | Net income 2022 | 113M 15.61M | EV / Sales 2021 | 6.97 x |
| Net cash position 2021 | 1.11B 154M | Net cash position 2022 | 1.25B 173M | EV / Sales 2022 | 4.31 x |
| P/E ratio 2021 |
76.5
x | P/E ratio 2022 |
70.9
x | Employees | 2,332 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 72.17% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.24% | ||
| 1 week | +4.95% | ||
| Current month | -0.43% | ||
| 1 month | -1.03% | ||
| 3 months | -6.63% | ||
| 6 months | -10.62% | ||
| Current year | -19.44% |
1 week
15.22
16.50
1 month
15.0516.65
Current year
12.8820.35
1 year
12.8821.77
3 years
12.8828.67
5 years
12.8834.77
10 years
12.8879.58
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Wang
CEO | Chief Executive Officer | 57 | 09-06-29 |
Xiao Ting Wang
DFI | Director of Finance/CFO | 42 | 22-05-24 |
Hai Bin Li
BRD | Director/Board Member | 53 | 16-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Jia Gong
CHM | Chairman | 59 | 22-03-25 |
Yong Wang
CEO | Chief Executive Officer | 57 | 09-06-29 |
Xin Yi Hou
BRD | Director/Board Member | 64 | 20-05-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 16.33 | +1.24% | 4,311,099 |
| 24-04-24 | 16.13 | +1.38% | 3,420,213 |
| 24-04-23 | 15.91 | +1.73% | 3,544,628 |
| 24-04-22 | 15.64 | +1.43% | 4,008,999 |
| 24-04-19 | 15.42 | -0.90% | 2,871,144 |
End-of-day quote Shanghai S.E., April 24, 2024
More quotes
VCANBIO CELL & GENE ENGINEERING CORP., LTD is a China-based company, principally engaged in the preparation, detection and storage of cells. The Company is also engaged in cell culture and gene detection and storage, as well as the production and sale of cytokines culture solutions, cosmetics and detection reagents. The Company conducts its businesses mainly within domestic markets.
Calendar
2024-04-25
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -19.44% | 1.04B | |
| -1.09% | 12.72B | |
| -12.53% | 7.5B | |
| +0.45% | 5.48B | |
| -1.37% | 4.61B | |
| +5.16% | 4.47B | |
| -51.93% | 3.28B | |
| +11.34% | 2.71B | |
| -19.05% | 2.02B | |
| -11.07% | 1.74B |
- Stock Market
- Equities
- 600645 Stock
